AbbVie, Celgene and 2 More Major Biotechs Reporting Earnings Thursday

Health and Healthcare

Published: April 26, 2017 11:30 am

Last Updated: January 12, 2020 12:37 pm

Earnings season is now in full swing, and we have put together a preview of some of the world’s largest biotechnology and pharmaceutical companies reporting their earnings on Thursday. With the markets running red-hot right now, it is no doubt that health care stocks are some that can benefit the most from this rising tide.

Over the past five, 10 and 20 years, the life sciences and bioproduction segments have outperformed the S&P 500 more often than not. Recently, we took a look at what one key analyst had to say about other companies in this segment that could continue to outperform the broad markets going forward.

Here we have included the Thomson Reuters consensus estimates for each stock, as well as some color and a recent trading history and consensus target for each stock.

AbbVie Inc. (NYSE: ABBV) is scheduled to report its first-quarter results before the markets open. The consensus estimates are $1.26 in earnings per share (EPS) and $6.48 billion in revenue. Shares were last seen at $65.88. The consensus price target is $71.28, and the 52-week range is $55.06 to $68.12.

Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) also is set to share its latest quarterly earnings in the morning. The consensus estimates call for a $1.23 in EPS on $827.2 million in revenue. Shares were at $122.88 on Wednesday, in a 52-week range of $109.12 to $157.02. The consensus price target is $161.70.

Bristol-Myers Squibb Co. (NYSE: BMY) is expected to reveal its first-quarter results early in the day as well. The consensus forecast calls for $0.74 in EPS and $4.72 billion in revenue. The stock recently traded at $54.59. The consensus price target is $55.76, and the 52-week range is $46.01 to $77.12.

And Celgene Corp. (NASDAQ: CELG) also will to share its latest quarterly earnings Thursday morning. The consensus estimates call for $1.64 in EPS and $3.04 billion in revenue. Shares were last trading at $125.85, in a 52-week range of $94.42 to $127.64. The consensus price target is $140.04.

Are You Still Paying With a Debit Card?

The average American spends $17,274 on debit cards a year, and it’s a HUGE mistake. First, debit cards don’t have the same fraud protections as credit cards. Once your money is gone, it’s gone. But more importantly you can actually get something back from this spending every time you swipe.

Issuers are handing out wild bonuses right now. With some you can earn up to 5% back on every purchase. That’s like getting a 5% discount on everything you buy!

Our top pick is kind of hard to imagine. Not only does it pay up to 5% back, it also includes a $200 cash back reward in the first six months, a 0% intro APR, and…. $0 annual fee. It’s quite literally free money for any one that uses a card regularly. Click here to learn more!

Flywheel Publishing has partnered with CardRatings to provide coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.